Prime Medicine (PRME) Preferred Stock Liabilities (2021 - 2022)
Prime Medicine (PRME) posted Preferred Stock Liabilities of $395.8 million for Q3 2022, up 101.78% on a QoQ basis from $196.2 million in Q2 2022, and up 98.25% year-over-year from $199.6 million in Q3 2021.
Prime Medicine (PRME) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
Prime Medicine's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $395.8 million for Q3 2022.
- Quarterly Preferred Stock Liabilities rose 98.25% year-over-year to $395.8 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $395.8 million (up 98.25% YoY) and the FY2021 annual result came in at $395.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities was $395.8 million for Q3 2022 at Prime Medicine, up from $196.2 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $395.8 million in Q4 2021 and bottomed at $196.2 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Prime Medicine | 525.98 Mn | 525.98 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 395.80 Mn |
| Jun 30, 2022 | 196.16 Mn |
| Mar 31, 2022 | 199.64 Mn |
| Dec 31, 2021 | 395.80 Mn |
| Sep 30, 2021 | 199.64 Mn |